In-Vitro and In-Vivo Establishment and Characterization of Bioluminescent Orthotopic Chemotherapy-Resistant Human Osteosarcoma Models in NSG Mice
Authors:
- Maria Eugénia Marques da CostaMCMaria Eugénia Marques da Costa
- Antonin MarchaisAMAntonin Marchais
- Anne Gomez-BrouchetAGAnne Gomez-Brouchet
- Bastien JobBJBastien Job
- Noémie AssounNANoémie Assoun
- Estelle Daudigeos-DubusEDEstelle Daudigeos-Dubus
- Olivia FromiguéOFOlivia Fromigué
- Conceição SantosCSConceição Santos
- Birgit GeoergerBGBirgit Geoerger
- Nathalie GasparNGNathalie Gaspar
Open Access
Abstract
Osteosarcoma, the most common bone malignancy with a peak incidence at adolescence, had no survival improvement since decades. Persistent problems are chemo-resistance and metastatic spread. We developed in-vitro osteosarcoma models resistant to chemotherapy and in-vivo bioluminescent orthotopic cell-derived-xenografts (CDX). Continuous increasing drug concentration cultures in-vitro resulted in five methotrexate (MTX)-resistant and one doxorubicin (DOXO)-resistant cell lines. Resistance persisted after drug removal except for MG-63. Different resistance mechanisms were identified, affecting drug transport and action mechanisms specific to methotrexate (RFC/SCL19A1 decrease, DHFR up-regulation) for MTX-resistant lines, or a multi-drug phenomenon (PgP up-regulation) for HOS-R/DOXO. Differential analysis of copy number abnormalities (aCGH) and gene expression (RNAseq) revealed changes of several chromosomic regions translated at transcriptomic level depending on drug and cell line, as well as different pathways implicated in invasive and metastatic potential (e.g., Fas, Metalloproteinases) and immunity (enrichment in HLA cluster genes in 6p21.3) in HOS-R/DOXO. Resistant-CDX models (HOS-R/MTX, HOS-R/DOXO and Saos-2-B-R/MTX) injected intratibially into NSG mice behaved as their parental counterpart at primary tumor site; however, they exhibited a slower growth rate and lower metastatic spread, although they retained resistance and CGH main characteristics without drug pressure. These models represent valuable tools to explore resistance mechanisms and new therapies in osteosarcoma.Keywords
Funding Information
- Ligue Contre le Cancer (Osteomics)
- Etoile de Martin (Osteomics)
- SFCE (Osteomics)
- Fédération Enfants et Santé (Osteomics)
- Une main Vers l'Espoir association (Osteomics)
- Foundation for Science and Technology (SFRH/BD/89137/2012)
This publication has 52 references indexed in Scilit:
- Mechanisms and insights into drug resistance in cancerFrontiers in Pharmacology, 2013
- The Genetics of OsteosarcomaSarcoma, 2012
- Functional characterization of osteosarcoma cell lines provides representative models to study the human diseaseLaboratory Investigation, 2011
- Genomic Alterations and Allelic Imbalances Are Strong Prognostic Predictors in OsteosarcomaClinical Cancer Research, 2010
- Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in OsteosarcomaPLOS ONE, 2010
- Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effortGenes, Chromosomes and Cancer, 2009
- Networking of differentially expressed genes in human cancer cells resistant to methotrexateGenome Medicine, 2009
- Mechanisms of gene amplification and evidence of coamplification in drug‐resistant human osteosarcoma cell linesGenes, Chromosomes and Cancer, 2008
- Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcomaExperimental and Molecular Pathology, 2008
- Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cellsAnnals of Oncology, 2004